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Inflammatory changes are analyzed in the anterior spinal cord and frontal cortex area 8 in typical spinal-predominant ALS
cases. Increased numbers of astrocytes and activated microglia are found in the anterior horn of the spinal cord and pyramidal
tracts. Significant increased expression of TLR7, CTSS, and CTSC mRNA and a trend to increased expression of IL10RA, TGFB1,
and TGFB2 are found in the anterior lumbar spinal cord in ALS cases compared to control cases, whereas C1QTNF7 and
TNFRSF1A mRNA expression levels are significantly decreased. IL6 is significantly upregulated and IL1B shows a nonsignificant
increased expression in frontal cortex area 8 in ALS cases. IL-6 immunoreactivity is found in scattered monocyte-derived
macrophages/microglia and TNF-𝛼 in a few cells of unknown origin in ALS cases. Increased expression and abnormal distribution
of IL-1𝛽 occurred in motor neurons of the lumbar spinal cord in ALS. Strong IL-10 immunoreactivity colocalizes with TDP-
43-positive inclusions in motor neurons in ALS cases. The present observations show a complex participation of cytokines and
mediators of the inflammatory response in ALS consistent with increased proinflammatory cytokines and sequestration of anti-
inflammatory IL-10 in affected neurons.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive age-
dependent neurodegenerative disease with an estimated inci-
dence of about 1–3/100,000 resulting in death on average
within 3–5 years of symptom onset. ALS is not a rare disease
with lifetime risk of 1 : 1000 and 2 : 1 male predominance.
Although ALS is primarily a motor neuron disease affecting
the upper (cortical) and lower (brain stem and spinal) motor
neurons with concomitant muscle atrophy, a proportion
of patients develop frontotemporal lobar degeneration and
occasionally other neurological symptoms. Therefore, ALS
is a multisystem degeneration with predominant motor
symptoms. About 8–10% of cases are inherited (fALS), the
majority of them autosomal dominant but some of them
recessive or X-linked. There is incomplete penetrance and
intra- and interfamilial variability as well as variability at the
age of onset and rate of progression. It has been suggested that
about 13% of sALS cases bear a gene mutation linked to fALS
[1, 2]. However, the cause of ALS in the majority of sporadic
cases is not known.
Inflammation is a constant molecular phenomenon in
ALS. This is manifested by a combination of altered systemic
and central nervous system responses [3–9].
Regarding systemic responses, activated monocyte/ma-
crophages [10], altered expression of chemokines in mono-
cytes [11], increased levels of CD4+ cells, and decreased
levels of CD8+ T lymphocytes [12] have been reported in
ALS. Altered expression of several cytokines and mediators
of inflammation has been reported in the serum although
with remarkable differences from one laboratory to another,
probably depending on the method used for determination.
Increased protein expression of IL-17A [13, 14], IL-23 [14],
IL-15 and IL-12 [14], chemokines [15], RANTES [16], IL-6
and TNF-𝛼 [17], TNF𝛼 and soluble receptors [18], and IL-6
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[19] has been separately reported in the serum of ALS cases.
However, only IL-18 and its endogenous inhibitor IL-18BP
among several members of the IL-1 family were identified in
a recent study [20].
Major inflammatory changes in the central nervous sys-
tem in ALS involve increased numbers of reactive astrocytes
and activated microglia in target regions such as the anterior
horn of the spinal cord, motor nuclei of the brainstem,
pyramidal tracts, and motor cortex, but also in other regions
such as the prefrontal cortex and thalamus [21–25]. Increased
inflammation has also been detected in vivo using the
radioligand [11C]-(R)-PK11195, in motor cortex, dorsolateral
prefrontal cortex, thalamus, and pons [26], and in tissue
samples in ALS [27]. Intrinsic inflammatory-related cells
in the spinal cord are accompanied by low numbers of
lymphocytes and other blood-derived cells [28, 29].
Increased protein levels of several cytokines and media-
tors of the inflammatory response have also been reported
in the CSF in ALS. These include IL-6 and IL-1𝛽 [30],
RANTES [16], chemokines [15], IL-8 [31], IL-23 [32], IL-17A
[13, 32], IL15 and IL-12 [14], chemokines [33], and IL-18BP
[20]. This heterogeneous representation further indicates
variations depending on themethods and products employed
in the different laboratories.
Increased CSF levels of these molecules may be due
to the active synthesis of inflammatory factors by intrinsic
inflammatory cells, mainly microglia [34–37]. In this line,
leukocyte common antigen (LCA), lymphocyte function
associate molecule 1 (LFA-1), and complement receptors CR3
and CR4 are increased in the spinal cord [3, 23], together
with cyclooxygenase 2 [38] and IFN𝛾 and LIGHT [39]
in ALS. Immunohistochemistry has also shown increased
expression of TLR2, TLR4, and RAGE in reactive glial
cells in both gray (ventral horn) and white matter of ALS
spinal cord. TLR2 was predominantly detected in cells of the
microglia/macrophage lineage, whereas the TLR4 and RAGE
were strongly expressed in astrocytes [40].
Curiously, studies of mRNA expression are scant. High
levels of mRNA and protein of classical complement path-
way, C1q and C4, as well as the downstream complement
components C3 and C5b-9, have been reported in ALS
samples [36]. RT-qPCR analysis has confirmed the increased
expression of both TLR2 and TLR4, and HMGB1 mRNA
level in ALS patients paralleling increased TLR2 and TLR4
protein expression [40]. mRNA studies in the cerebral cortex
are rarer, although upregulation of several cytokines and
IFN𝛽, and encoding proteins involved in antigen presentation
including major histocompatibility complex (MHC) class I
molecules, has been reported in motor cortex [41].
The objective of the present study was to analyze with a
large panel of mRNA probes the expression of cytokines and
mediators of the immune response in the anterior lumbar
spinal cord and frontal cortex area 8 in cases with sALS
classical forms. The selection of probes was based on the fact
that these are the same probes used to analyze inflammatory
responses in other neurodegenerative diseases including
Parkinson’s disease, Alzheimer’s disease, and Creutzfeldt-
Jakob’s disease [42–44]. This approach would permit the
identification of disease-dependent commonalities and dif-
ferences in the inflammatory responses examined by using
the same probes in the same laboratory.The studywas accom-
panied by immunohistochemical localization of selected
inflammatory mediators in the anterior lumbar spinal cord.
The immediate purposewas to assess inflammatory responses
in two separate regions in ALS cases. The final goal was
to gain understanding about the characteristics of intrinsic
inflammation among different neurodegenerative diseases
with abnormal protein aggregates to have basic information
to provide a rationale for the specific use of eventual inflam-
mation modulatory therapies in the different disorders.
2. Material and Methods
2.1. Brain and Spinal Cord Tissue Samples. Brain and spinal
cord tissue samples were obtained from the Institute of
Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank)
following the Spanish legislation and after the approval of
the local ethics committee. The postmortem delay ranged
from 2 h 10min to 16 h 30min. After brain removal from
the skull, one hemisphere was immediately cut in coronal
sections, 1 cm thick, and selected areas of the encephalon
were rapidly dissected, frozen on metal plates over dry
ice, placed in individual air-tight plastic bags, numbered
with water-resistant ink, and stored at −80∘C until use. The
other hemisphere was fixed by immersion in 4% buffered
formalin for 3 weeks. Transversal sections of the cervical,
thoracic, lumbar, and sacral spinal cortex were alternatively
frozen at −80∘C or fixed by immersion in 4% buffered
formalin. Neuropathological examination in all cases was
routinely performed on twenty selected dewaxed paraffin
sections comprising different regions of the cerebral cortex,
diencephalon, thalamus, brain stem, and cerebellum and
several levels of the spinal cord, which were stained with
haematoxylin and eosin, Klüver-Barrera, and, for immuno-
histochemistry to microglia, glial fibrillary acidic protein, 𝛽-
amyloid, phosphorylated tau (clone AT8), 𝛼-synuclein, TDP-
43, ubiquitin, and p62.
ALS cases (𝑛 = 14; mean age 64.4 years; 7 men and 7
women) had typical spinal-predominant clinical course and
typical neuropathological findings of sporadic amyotrophic
lateral sclerosis with TDP-43-immunoreactive intraneuronal
inclusions [1]. Although the intensity of lesions in the pyrami-
dal tracts and anterior spinal horn varied from one individual
to another, cases were selected to minimize individual vari-
ations. Cases with cognitive impairment were not included
in the present series. Neuropathological study also served to
eliminate cases with combined pathologies including fron-
totemporal lobar degeneration associated with TDP-43pathy
and cases with Alzheimer’s disease- (AD-) related pathology
at stages higher than I-II of Braak and Braak. Age-matched
control cases (𝑛 = 19; mean age 64.8 years; 9 men and 10
women) had not suffered from neurologic, psychiatric, or
metabolic diseases (including metabolic syndrome) and did
not have abnormalities in the neuropathological examina-
tion excepting sporadic Alzheimer’s disease- (AD-) related
pathology stages I-II of Braak andBraak.ALS caseswithmore
advanced stages of sporadic AD-related pathology were not
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Table 1: Summary of clinical and pathological data in the present
series.
Case Pathology Sex Age P-M RIN FC RIN SC
1 0 M 43 5 h 55m 8.1 6.5
2 0 M 47 4 h 55m 7.8
3 0 M 46 15 h 7.7 6
4 0 F 71 8 h 30m 7.4 6
5 0 M 52 3 h 8.2
6 0 M 64 8 h 30m 7.7
7 0 M 67 5 h 7.4
8 0 F 49 7 h 8.2
9 0 F 75 3 h 7.7
10 0 F 64 5 h 7.1
11 AD II F 86 4 h 15m
12 AD I F 79 3 h 35m
13 AD I F 79 6 h 25m 6.9
14 AD II F 77 3 h 15m
15 AD II F 76 5 h 45m
16 AD I F 59 11 h 20m 6.9
17 AD I M 76 6 h 30m 6.8
18 AD I M 56 7 h 10m 6.3
19 AD II M 66 4 h 55m 6.4
20 ALS/ADI F 76 13 h 6.6
21 ALS F 59 14 h 15m 6.5
22 ALS M 54 4 h 50m 7.7
23 ALS M 70 3 h 7.2 7.2
24 ALS M 56 10 h 50m 7.4
25 ALS M 77 4 h 30m 8 7.9
26 ALS/AD II F 75 4 h 5m 7
27 ALS F 57 10 h 7.4 6.7
28 ALS F 56 3 h 45m 8.3 8.3
29 ALS/AD II M 57 4 h 6.5
30 ALS/AD II F 79 2 h 10m 7.4
31 ALS M 64 16 h 30m 7.4 7
32 ALS M 59 3 h 15m 7.8 7.5
33 ALS F 63 13 h 50m 7.4 6.9
Thirty-three cases are analyzed corresponding to 19 controls and 14 amy-
otrophic lateral sclerosis (ALS) cases. SomeALS cases have concomitant AD-
related pathology at stages I-II of Braak (AD I-II), and for this reason some
control cases with similar stages of AD-related pathology are included in the
study of the anterior lumbar spinal cord. However, only cases without AD-
related pathology are selected for study in the frontal cortex area 8 (see text).
M: male; F: female; P-M: postmortem delay (hours, minutes); FC: frontal
cortex area 8; SC: anterior lumbar spinal cord; RIN: RNA integrity number.
considered in the present series to avoid overlap betweenALS
and AD in the frontal cortex. A summary of cases analyzed is
shown in Table 1.
Biochemical studies were focused on the frontal cortex
area 8 and anterior half of the lumbar spinal cord mainly
comprising the anterior horns.
2.2. RNA Extraction and Purification. Extraction of RNA
was performed with RNeasy Lipid Tissue Mini Kit (Qiagen,
Hilden, DE) following the instructions provided by the
supplier and performing the optional DNase digest to avoid
extraction and later amplification of genomic DNA. The
concentration of each sample was measured at 340 nm with
the NanoDrop 2000 spectrophotometer (Thermo Scientific,
Waltham, Massachusetts, USA). The RNA integrity number
(RIN) was measured with the Agilent 2100 Bioanalyzer
(Agilent, Santa Clara, California, USA), which is shown in
Table 1.
2.3. Retrotranscription Reaction. The process was performed
with the High-Capacity cDNA Archive kit (Applied Biosys-
tems, Foster City, California, USA) according to themanufac-
turer’s instructions and using Gene Amp 9700 PCR System
thermocycler (Applied Biosystems). A negative control was
used without reverse transcriptase to rule out any DNA
contamination.
2.4. Real Time qPCR. RT-qPCR assays were done in duplicate
on cDNA samples obtained from the retrotranscription reac-
tion and were performed in 384-well optical plates (Applied
Biosystems) utilizing the ABI Prism 7900 HT Sequence
Detection System (Applied Biosystems). 20x TaqMan Gene
Expression Assays and 2x TaqMan Universal PCR Master
Mix (Applied Biosystems) were used for performing the
amplification reactions. TaqMan probes used in this study
are shown in Table 2. The selection of these probes was
based on parallel studies using the same probes carried
out in other neurodegenerative diseases, particularly AD,
Parkinson’s disease, andCreutzfeldt-Jakob’s disease, for future
comparative purposes.The reactions were performed follow-
ing the sequence of temperature and time: 50∘C for 2min,
95∘C for 10min, 40 cycles at 95∘C for 15 s, and 60∘C for
1min. TaqMan PCRs were recorded using the Sequence
Detection Software (SDS version 2.3, Applied Biosystems).
Threshold cycle (CT) data for each sample were analyzed.
First, delta CT (ΔCT) values were calculated by normalizing
theCTvalues of each target genewith the endogenous control
𝛽-glucuronidase (GUS-𝛽) for normalization [45]. Second,
ΔΔCT values were obtained with the ΔCT of each sample
minus the mean ΔCT of the population of control samples
(calibrator samples). The fold-change was determined using
the equation 2−ΔΔCT.
2.5. Immunohistochemistry. Formalin fixed, paraffin embed-
ded tissue sections 4-5 microns thick of anterior lumbar
spinal cord from ALS cases and controls (𝑛 = 6 per group)
were dewaxed and processed for CD68, IBA1, IL-6, IL-10, IL-
1𝛽, and TNF-𝛼 for immunohistochemistry.The sections were
incubated with 2% hydrogen peroxide and 10% methanol for
30min at room temperature, followed by 5% normal serum
for 2 h. Then the sections were incubated overnight with one
of the primary antibodies. Monoclonal mouse anti-human
CD68 clone PG-M1CD68 antibody (Dako, Agilent Technolo-
gies, Barcelona, Spain) was used at a dilution of 1/50. IBA-
1 rabbit, polyclonal antibody (Wako, Richmond, VA, USA)
was used at a dilution of 1 : 250. Rabbit polyclonal antibodies
against IL-6 (IL-6, ab6672, Abcam) were diluted 1/100, IL-
10 (AP52181PU-N, Acris) 1/1,000; IL-1𝛽 (IL1 beta, ab9722,
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Table 2: Abbreviation of genes examined and full names and sequences of TaqMan probes used in the present study.
Gene Full name Sequence of TaqMan probes
GUS-𝛽 𝛽-glucuronidase GCTACTACTTGAAGATGGTGATCGC
C1QTNF7 C1q and tumor necrosis factor related protein 7 GGGAACTGCAGGTTTGAGAGGTAAG
C3AR1 Complement component 3a receptor 1 TCTCAGTTTTTTGAAGTTTAGCAAT
CSF3R Colony stimulating factor 3 receptor GCTGCTCCCCGGAAGTCTGGAGGAG
CTSC Cathepsin C CGGTTATGGGACCACAAGAAAAAAA
CTSS Cathepsin S AAAGCCATGGATCAGAAATGTCAAT
IL1B Interleukin 1𝛽 CAGATGAAGTGCTCCTTCCAGGACC
IL6 Interleukin 6 TCAGCCCTGAGAAAGGAGACATGTA
IL6ST Interleukin 6 signal transducer CAAAGTTTGCTCAAGGAGAAATTGA
IL8 Interleukin 8 GTGTGAAGGTGCAGTTTTGCCCAAGG
IL10 Interleukin 10 AATAAGCTCCAAGAGAAAGGCATCT
IL10RA Interleukin 10 receptor 𝛼 CAGTGTCCTGCTCTTCAAGAAGCCC
TGFB1 Transforming growth factor 𝛽1 AGTACAGCAAGGTCCTGGCCCTGTA
TGFB2 Transforming growth factor 𝛽2 GCACAGCAGGGTCCTGAGCTTATAT
TLR4 Toll-like receptor 4 GGAGCCCTGCGTGGAGGTGGTTCCT
TLR7 Toll-like receptor 7 AGACTAAAAATGGTGTTTCCAATGT
TNF-𝛼 Tumor necrosis factor 𝛼 TGGCCCAGGCAGTCAGATCATCTTC
TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A CTCCTGTAGTAACTGTAAGAAAAGC
Abcam) 1/200; mouse monoclonal antibodies against TNF-
𝛼 (ab1793, Abcam) were diluted 1/10. Peroxidase reaction was




. Control of the
immunostaining included omission of the primary antibody;
no signal was obtained following incubation with only the
secondary antibody.
2.6. Double-Labelling Immunofluorescence and Confocal
Microscopy. Double-labeling immunofluorescence was
carried out on dewaxed sections, 4 microns thick, which
were stained with a saturated solution of Sudan black B
(Merck, DE) for 15min to block the autofluorescence of
lipofuscin granules present in cell bodies and then rinsed
in 70% ethanol and washed in distilled water. Antigenicity
enhancement was performed by boiling the sections in
citrate buffer. The sections were next blocked for 30min at
room temperature with 10% fetal bovine serum diluted in
PBS. Then, the sections were incubated at 4∘C overnight
with rabbit polyclonal anti-IL-10 (AP52181PU-N, ACRIS)
and anti-phospho TDP-43 mouse monoclonal antibody
(pS409/410-1; Cosmo Bio Co, Japan). After washing, the
sections were incubated with Alexa488 or Alexa546 (1 : 400,
Molecular Probes, USA) fluorescence secondary antibodies
against the corresponding host species. Nuclei were stained
with DRAQ5 (1 : 2,000, BioStatus, GB). After washing,
the sections were mounted in Immuno-Fluore mounting
medium (ICN Biomedicals, USA), sealed, and dried
overnight. Sections were examined with a Leica TCS-SL
confocal microscope.
2.7. Gel Electrophoresis and Western Blotting. Samples of
the spinal cord were homogenized in RIPA lysis buffer
(50mM Tris/HCl buffer, pH 7.4 containing 2mM EDTA,
0.2% Nonidet P-40, 1mM PMSF, protease, and phosphatase
inhibitor cocktails, Roche Molecular Systems, USA). The
homogenates were centrifuged for 15min at 13,000 rpm.
Protein concentration was determined with the BCAmethod
(Thermo Scientific). Equal amounts of protein (20 𝜇g) for
each sample were loaded and separated by electrophoresis
on sodiumdodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (10%) gels and transferred onto nitrocellulose
membranes (Amersham, Freiburg, Germany). Nonspecific
bindings were blocked by incubation in 3% albumin in PBS
containing 0.2% Tween for 1 h at room temperature. After
washing, membranes were incubated overnight at 4∘C with
the antibodies against IL-1𝛽 (1 : 5,000, Abcam, Cambridge,
UK), IL-6 (1 : 1,000, Abcam), and cathepsin S (1 : 500, Santa
Cruz Biotechnology, Dallas, TX, USA). Protein loading was
monitored using an antibody against 𝛽-actin (1 : 30,000,
Sigma-Aldrich, St. Louis, MO, USA). Membranes were
then incubated for 1 h in the appropriate HRP-conjugated
secondary antibodies (1 : 2,000, Dako, Glostrup, Denmark),
and immunocomplexes were revealed by chemiluminescence
reagent (ECL, Amersham GE Healthcare, Buckinghamshire,
UK). Densitometric quantification was carried out with
TotalLab version 2.01 software (Pharmacia, Sweden). Bands
were normalized to𝛽-actin.ThirteenALS samples and twelve
control samples were analyzed.
2.8. Statistical Analysis. The normality of distribution of
the mean fold-change values obtained by RT-qPCR was
analyzed with the Kolmogorov-Smirnov test. Results were
analysed with Student’s 𝑡-test. Differences between groups




Table 3: Results of mRNA expression assessed by RT-qPCR using GUS-𝛽 for normalization.
Frontal cortex Spinal cord
Control ALS 𝑝 value Control ALS 𝑝 value
Proinflammatory signaling
Complement system
C1QTNF7 1.14 ± 0.63 1.42 ± 0.89 1.07 ± 0.43 0.52 ± 0.41 ∗
C3AR1 1.23 ± 0.66 1.53 ± 0.94 1.00 ± 0.10 0.94 ± 0.41
Colony stimulating factor
CSF3R 1.16 ± 0.59 1.38 ± 0.69 1.07 ± 0.45 1.37 ± 0.88
Toll-like receptor
TLR4 1.29 ± 0.85 0.93 ± 0.34 1.26 ± 0.91 0.95 ± 0.19
TLR7 1.16 ± 0.59 1.05 ± 0.50 1.08 ± 0.39 2.12 ± 0.90 ∗
Cathepsins
CTSC 1.15 ± 0.64 1.62 ± 0.91 1.11 ± 0.52 1.71 ± 0.67 ∗
CTSS 1.26 ± 0.83 1.36 ± 0.74 1.05 ± 0.35 2.01 ± 0.93 ∗∗
Interleukins
IL1B 1.32 ± 0.89 3.29 ± 2.70 0.053 1.27 ± 0.81 1.13 ± 1.05
IL6 1.42 ± 1.29 5.11 ± 4.73 ∗ 1.69 ± 2.19 3.04 ± 2.97
IL6ST 1.04 ± 0.33 1.23 ± 0.48 1.05 ± 0.35 0.84 ± 0.17
IL8 2.19 ± 3.91 1.06 ± 1.16 1.46 ± 1.43 1.41 ± 1.26
TNF family
TNF-𝛼 ND ND 1.11 ± 0.57 0.95 ± 0.31
TNFRSF1A 1.10 ± 0.52 1.41 ± 0.86 1.04 ± 0.30 0.71 ± 0.11 ∗
Anti-inflammatory signaling
IL-10 family
IL10 1.17 ± 0.58 1.40 ± 0.68 1.20 ± 0.70 1.54 ± 0.61
IL10RA 1.13 ± 0.56 1.27 ± 0.75 1.07 ± 0.39 1.55 ± 0.71 0.087
TGF beta family
TGFB1 1.08 ± 0.45 1.19 ± 0.54 1.01 ± 0.15 1.73 ± 0.85 0.063
TGFB2 1.18 ± 0.68 1.41 ± 0.69 1.01 ± 0.17 1.64 ± 0.90 0.07
TLR7, CTSS, and CTSC mRNA are significantly upregulated, and C1QTNF7 and TNFRSF1A mRNA are significantly downregulated in the anterior lumbar
spinal cord in ALS; a tendency to increase is also observed for IL10RA, TGFB1, and TGFB2. IL6 is significantly upregulated and IL1B shows a trend to increase
in the frontal cortex area 8 in ALS compared to controls. Values are calculated with theΔΔCTmethod, usingGUS-B as housekeeping gene and control samples
as references. ND: not detectable. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01 versus controls.
3. Results
3.1. mRNA Expression Assessment by RT-q PCR. 17 mRNAs
were selected in this study and their expression was tested
in the frontal cortex (13 ALS cases and 14 control cases) and
the anterior half of the lumbar spinal cord (12 ALS cases
and 9 control cases). The study included members of the
complement system (C1QTNF7, C3AR1), colony stimulating
factors (CSF3R), Toll family (TLR4, TLR7), cytokines (IL6,
IL6ST, IL1B), TNF𝛼 family (TNFRSF1A, TNF-𝛼), IL10 (IL10,
IL10RA), TGF𝛽 family (TGF𝛽1, TGF𝛽2), and cathepsins
(CTSS, CTSC). GUS-𝛽 was used for normalization. Some
samples from control and ALS patients had also AD-related
pathology at stages I-II of Braak and Braak. In order to
elucidate whether first stages of AD-related pathology might
affect the inflammatory process in the spinal cord and
therefore distort the specific inflammatory response related
to ALS, a preliminary AD versus non-AD comparison in
control and ALS samples of the spinal cord was performed.
No differences due to AD-related pathology were observed
in the spinal cord between control and ALS cases (Supple-
mentary Table I in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/573784).
3.1.1. Anterior Lumbar Spinal Cord. TLR7, CTSS, and CTSC
mRNA significant upregulation (𝑝 < 0.05) was found in
the anterior lumbar spinal cord in ALS cases compared to
control cases. IL10RA,TGFB1, andTGFB2 showed a tendency
to increase without statistical significance. C1QTNF7 and
TNFRSF1A mRNA were downregulated (𝑝 < 0.05). No
modification was found in the expression of the rest of the
genes studied in this region (Table 3).
3.1.2. Frontal Cortex Area 8. Since previous studies have
shown early modifications in mRNA cytokine expression in
the frontal cortex at early stages of AD-related pathology
[44], studies of mRNA in this region were limited to control



















































Figure 1: Quantification of western blotting of IL1𝛽 (a), IL-6 (b), and cathepsin s (c) in lumbar spinal cord shows no significant differences
in control and ALS cases. 𝛽-actin levels were used as loading control. Densitometric quantifications are expressed as mean values ± SD.
remaining cases (ALS = 9; control = 9) was considered
sufficient for comparative analysis.
IL6 was significantly upregulated (𝑝 < 0.05) and
IL1B showed a nonsignificant increase in ALS cases when
compared to control cases (Table 3).
3.2. Protein Quantification by Western Blotting. The total
levels of three of proteins were quantified by western blotting.
No significant difference was observed between control and
ALS regarding IL-1𝛽, IL-6, and cathepsin S protein levels
(Figures 1(a)–1(c)).
3.3. Immunohistochemistry, Double-Labelling Immunofluores-
cence, and Confocal Microscopy. CD68 immunohistochem-
istry revealed that the phenotype of monocyte derived
macrophages/microglia was ramified and amoeboid in
the anterior lumbar horn, anterior root, and direct and
crossed pyramidal tracts of the spinal cord in ALS (Figures
1(a)–1(c)). Differences in number were assessed regarding
IBA1-immunoreactive cells; increased numbers of mono-
cyte derived macrophages/microglia (543.1 ± 36.2 cells/mm2
in ALS versus 312.6 ± 19.3 cells/mm2 in controls), in
addition to high predominance of amoeboid cells, were
found in the pyramidal tracts of the spinal cord in ALS
(Figures 2(d) and 2(e)). Yet TNF-𝛼 was restricted to a few
round cells of unknown origin (Figure 2(f)). Strong IL-6
immunoreactivity occurred in the wall of the blood vessels
(Figure 2(g)) and in scattered glial cells with the morphology
of microglia/macrophage in ALS (Figures 2(g) and 2(h)).
Increased IL-1𝛽 immunoreactivity was observed in motor
neurons in ALS (118.7 ± 24.5 cells/mm2) when compared
to controls (64.3 ± 15.0 cells/mm2); abnormal distribution
of IL-1𝛽 was also found in a few motor neurons of the
lumbar spinal cord only in ALS (Figures 2(i) and 2(j)). IL-
10 immunoreactivity was present in neurons in control (41.5
± 4.3 cells/mm2) and ALS cases (63.5 ± 20.2 cells/mm2).
Curiously, increased IL-10 immunoreactivity was seen in
cytoplasmic inclusions reminiscent of ubiquitinated, TDP-
43-positive inclusions currently seen in motor neurons in
sALS (Figures 2(k)–2(o)).
Double-labelling immunofluorescence and confocal
microscopy further supported colocalization of IL-10 and
phosphorylated TDP-43 Ser409-410 in globular and skein-
like inclusions of motor neurons in ALS, involving about
80% of TDP-43-immunoreactive inclusions (Figure 3). No
increased IL-10 immunoreactivity has been seen in glial cells







Figure 2: (a–c): CD68 immunohistochemistry shows amoeboid monocyte derived macrophages/microglia in the anterior lumbar horn (a
and b) and pyramidal tracts (c) of the lumbar spinal cord in control (a) and ALS (b and c). (d and e) IBA1 stains immunoreactivity is present
in large numbers of monocyte derivedmacrophages/microglia in the lateral pyramidal tract in control (D) and ALS cases with predominance
of amoeboid cells in disease. (f) TNF-𝛼 is localized in a few round cells of undetermined origin. (g–i) IL-6 immunoreactivity is found in the
wall of blood vessels (g) and in scattered microglial cells (h and i). (j and k) IL-1𝛽 immunoreactivity is present in neurons in control (j) and
ALS cases but increased immunoreactivity and abnormal distribution of IL-1𝛽 is observed in a few motor neurons of the lumbar spinal cord
only in ALS (k). (l–o) Strong IL-10 immunoreactivity is seen in cytoplasmic inclusions in ALS reminiscent of ubiquitinated, TDP-43-positive
inclusions currently found in motor neurons in sALS. Paraffin sections, slight haematoxylin counterstaining, bar in (o) valid for all figures =







Figure 3: Double-labelling immunofluorescence and confocal microscopy show partial colocalization of IL-10 (green, a, d, g) and
phosphorylated TDP-43 Ser409-410 (red, b, e, h) in globular and skein-like inclusions in motor neurons in ALS cases; merge (c, f, i); nuclei
(blue) are with DRAQ5; bar = 25 𝜇m.
4. Discussion
The present findings demonstrate intrinsic regulation of
cytokines and mediators of the immune response in the
anterior part (roughly anterior horn) of the lumbar spinal
cord and frontal cortex area 8 in ALS cases compared to age-
matched controls. Significant increased expression of TLR7,
CTSS, and CTSCmRNA and a trend to increased expression
of IL10RA, TGFB1, and TGFB2 were found in the anterior
lumbar spinal cord in ALS cases compared to control cases,
whereas C1QTNF7 and TNFRSF1A mRNA expression levels
are significantly decreased. IL6 is significantly upregulated
and IL1B shows a nonsignificant increased expression in
frontal cortex area 8 in ALS cases when compared to control
cases. The analysis of the frontal cortex area 8 is considered
pertinent as it is vulnerable to ALS and major target of cases
with associated frontotemporal lobar degeneration (FTLD)
[1]. The present findings further show upregulation of key
cytokines even in cases with no concomitant FTLD.
These results indicate regional differences in the intrinsic
inflammatory response in ALS with higher deregulation in
the anterior lumbar spinal cord in comparison to the frontal
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cortex area 8. Interestingly, not the same mediators were
equally deregulated in the spinal cord and frontal cortex.
No relation between altered mRNA expression and total
protein contents of IL-1𝛽, IL-6, and cathepsin S is found
in ALS cases. Incomplete correlation between mRNA and
protein values can be explained by the modulation of
mRNA translation by several species of noncoding RNAs.
Protein expression of regulated cytokines by microRNAs has
been reported in ALS [46]. However immunohistochemistry
has shown increased IL-6 immunoreactivity in scattered
cells with monocyte derived macrophages/microglia mor-
phology. Altered IL-1𝛽 immunoreactivity, consistent with
cytoplasmic aggregates, occurred in a few motor neurons
in ALS. These findings together with monocyte derived
macrophages/microglia morphology and increased TNF-𝛼
immunoreactivity in a few mononuclear cells of unknown
origin in the anterior horn in ALS support the idea that
monocyte derived macrophages/microglia at end-stages of
ALS have cytotoxic properties [25, 34, 35, 37]. Increased IL-1𝛽
and IL-6 protein levels have also been detected in the CSF in
ALS [30], thus suggesting secretion of these factors from the
nervous system to the CSF.
IL-6 has anti-inflammatory and proinflammatory effects
[47, 48]. IL-6 binds to the IL-6 receptor which, in turn, binds
to the protein gp130, thus producing a restricted response
in the presence of IL-6 receptor; this is the classic signaling
pathway modulating anti-inflammatory responses. However,
only a few cells express the IL-6 receptor whereas all cells bear
gp130 protein on the cell surface. Direct activation of IL-6 of
gp130 produces an extended response with damaging conse-
quences [49, 50]. Transsignaling is a dominant mechanism
for the pathogenic actions of interleukin 6 in the brain [51].
IL-1𝛽 is a proinflammatory cytokine that can produce
structural damage to neurons and neuronal dysfunction
by acting on glutamate-mediated excitatory postsynaptic
currents [52–54]. Chronic administration of IL-1𝛽 leads to
neurodegeneration [55]. Chronic increased expression of
both cytokines may produce a harmful effect on motor
neurons in the ALS context.
Previous studies have shown that deregulation of TDP-
43 and p65 subunits triggers NF𝜅B-mediated pathogenic
pathways in the spinal cord of ALS cases and that TDP-43
also increases the production of proinflammatory cytokines
in microglia under appropriate settings [56]. An unexpected
finding in the present study was the colocalization of IL-
10 and TDP-43-positive cytoplasmic inclusions in anterior
horn motor neurons in ALS. TDP-43 participates in IL-6 and
IL-10 processing at the level of the subnuclear body called
the interleukin 6 and 10 splicing activating compartment
which is a nuclear site of cytokine RNA production and
stability [57]. But to our knowledge no TDP-43 and IL-
10 protein interactions have ever been reported. IL-10 is
a potent anti-inflammatory cytokine that regulates various
anti-inflammatory pathways [58–60]. However, the present
findings show that IL-10 is sequestered at the TDP-43-
immunoreactive inclusions in ALS motor neurons, thus
suggesting loss of its potential beneficial function.
Neuroinflammation has also been examined using the
same probes in several regions and stages of disease
progression in Alzheimer’s disease, Parkinson’s disease,
and Creutzfeldt-Jakob’s disease [42–44]. Those studies have
shown region- and stage-dependent differences in the inflam-
matory responses but also disease-dependent inflammatory
profiles. Moreover, these patterns differ from those identified
here in the frontal cortex area 8 and anterior lumbar spinal
cord in ALS at terminal stages. Therefore, inflammation-
related responses are not identical and homogeneous through
different neurodegenerative diseases with abnormal protein
aggregates, but rather they manifest specific patterns. The
patterns also vary with disease progression in human diseases
and related animal models [43, 44]. Since only ALS at
terminal stages was explored in the present study, there is
no information regarding inflammatory changes with disease
progression in human ALS cases.
Inflammation in ALS is a very complex phenomenon [5,
8, 9]. Previous clinical trials using unique anti-inflammatory
compounds have produced limited benefits [61–63] with the
exception of Tocilizumab, an inhibitor of IL-6 receptor that
has been shown to decrease inflammation somewhat in ALS
[64, 65]. However, IL-6 is not the only cytokine involved in
ALS, and combined therapies are probably needed to cope
with the multiple pathways and variegated molecules that
converge in the process of inflammation in ALS.
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